The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age

High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung cancer (NSCLC). As host immunity is also significant to eliminate cancer cells, however, i...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Biomark Res
Päätekijät: Wu, Yongfeng, Xu, Jinming, Xu, Jiawei, Wang, Yiqing, Wang, Luming, Lv, Wang, Hu, Jian
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2020
Aiheet:
Letter to the Editor
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7146978/
https://ncbi.nlm.nih.gov/pubmed/32308981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00188-2
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia